J&J’s Carvykti and BMS’ Abecma Win FDA Approvals for Earlier Use in Multiple Myeloma
XTalks
APRIL 11, 2024
Moreover, rather than producing antibodies, the cancer cells produce abnormal proteins that can cause complications. In last month’s call, Legend CEO Ying Huang, PhD, shared that the partners are aiming to increase manufacturing capacity at their New Jersey plant.
52 
Let's personalize your content